Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR)

Core Viewpoint - Arcoma AB has successfully completed a directed share issue, raising approximately SEK 11.0 million (~ EUR 1 million) to enhance its growth strategy and strengthen its shareholder base with Eiffel Investment Group as a new major investor [2][4][5]. Summary by Sections Directed Share Issue - The Board of Directors has resolved to issue a total of 1,122,950 new shares, fully subscribed by funds managed by Eiffel Investment Group, making it one of Arcoma's largest shareholders [2][3]. - The subscription price for the new shares is set at 9.76 SEK per share, representing a premium of approximately 4.3% compared to the closing price on 24 June 2025 [3][8]. Use of Proceeds - The net proceeds from the directed share issue will be utilized to expand sales resources, invest in product development and innovation, and accelerate acquisition strategies [4][5]. Strategic Importance - The addition of Eiffel Investment Group as a strategic shareholder is viewed as a strong endorsement of Arcoma's business model and growth strategy, enhancing the company's ownership structure with an international institutional investor [5][6]. - The Board of Directors assessed that a directed share issue is more advantageous than a rights issue, as it is less time-consuming and reduces exposure to market volatility [6][7]. Financial Impact - The directed share issue will increase the number of outstanding shares from 13,185,560 to 14,308,510, resulting in a dilution of approximately 7.8% [10]. - The share capital will rise from SEK 26,371,120 to SEK 28,617,020 [10]. Company Overview - Arcoma is a leading provider of integrated digital X-ray systems, known for high quality and advanced technology, with over 3,500 systems installed worldwide [11].